胰腺癌分子靶向治疗进展

胰腺癌在胃肠道肿瘤中预后差，5年生存率不到5％，发病率呈逐渐上升趋势。治疗主要是外科手术、化疗和放疗相结合的综合治疗，但目前常规治疗效果有限，因此针对胰腺癌生物学特性进行治疗是改善预后的关键。随着靶向治疗的进展，VEGF单克隆抗体和EGFR抑制剂在临床试验中都表现出较好的前景。其他靶向药物，如沙利度胺、基质金属蛋白酶抑制剂、COX-2抑制剂和法尼基转移酶抑制剂还在研究之中。分子靶向治疗将为胰腺癌的治疗提供新的机会。

Molecularly targeted therapy for pancreatic cancer

Pancreatic cancer has the poorest prognosis among common gastrointestinal malignancics with a 5-year overall survival of less than 5%.Its incidence increases gradually in recent decades.The combined modality therapy play a main role in the treatment of pancreatic cancer,although the outcome remains poor.New agents target against VEGF and EGFR are currently being evaluated in trials and have showed good results.Othor agents such as thalidomide,MMPs,COX-2 inhibitor,and farnesyl protein transferase inhibitor are still under investigation.The development of molecularly targeted therapy will bring new future for the prevention and treatment of to pancreatic cancer.